



To

Date: 29.12.2025

**BSE Limited
P. J. Towers,
Dalal Street,
Mumbai – 400001.**

Dear Sir / Madam,

Sub: Closure of Trading Window under SEBI (Prohibition of Insider Trading) Regulations, 2015

Unit: Oxygenta Pharmaceutical Limited (Scrip Code: 524636)

With reference to the subject cited and pursuant to the Company's Code of Conduct for Prevention of Insider Trading adopted by the Company under SEBI (Prohibition of Insider Trading) Regulations, 2015 the trading window for dealing in the securities of the Company will remain closed from 01.01.2026 till 48 hours after the declaration of un-audited Financial Results for the Quarter ending 31.12.2025 for all designated persons, their immediate relatives and all connected persons covered under the Company's Code of Conduct.

The Board Meeting will be scheduled, inter-alia, to consider and approve the unaudited Financial Results for the quarter ending December 31, 2025.

Accordingly, an intimation regarding the notice of Board Meeting shall be sent separately to the Stock Exchange. Further, the designated persons have been intimated not to trade in the securities of the Company during the above said period of closure of trading window.

This is for the information and records of the Exchange, please.

Thanking you.

**Yours faithfully,
For Oxygenta Pharmaceutical Limited**

**Kumkum Bajaj
Company Secretary & Compliance Officer
M No. A76548**

OXYGENTA PHARMACEUTICAL LIMITED (Subsidiary of **VIRUPAKSHA ORGANICS LIMITED**)

(An ISO 9001:2015, ISO 14001:2018 and ISO 45001:2015 Certified Company)

Regd off.& Factory: Sy.No. 252/1, Aroor (V), Sadasivapet (M), Sangareddy (Dist)-502 291, Telangana, INDIA. Tel: 08455-250080

Corp. Office: Level-1, Plot No. B1 & B2, IDA Gandhi Nagar, Kukatpally, Hyderabad – 500 037, Telangana, INDIA.

E-Mail id: info@oxygentapharma.com. Website: www.oxygentapharma.com,

Phone 040-23073417, CIN: L24110TG1990PLC012038